BRCA Gene May Predict Drug Resistance in Ovarian Cancer, Study Finds
BRCA 1 and BRCA 2 are gene mutations long associated with high risk for breast and ovarian cancer. Now, researchers at the University of Pennsylvania have found new evidence that it might also predict treatment resistance in ovarian cancers.
Breast cancer and ovarian cancer are both very serious and devastating diseases. The National Cancer Institute estimates that more than 250 thousand people will be diagnosed with breast cancer this year, and over 40 thousand will die from the disease.
Ovarian cancer is less common, with a projected 22, 440 new cases. However, it carries a much higher mortality rate. There will be an expected 14 thousand deaths or more this year from ovarian cancer. Most of these patients are diagnosed late in the disease, making their recovery dependent on getting the right treatment, fast. That's why drug resistant tumors pose a huge problem.